In 2026, Turkey continues to delay integrating the human papillomavirus (HPV) vaccine into its national vaccination program, while more than 140 countries have already adopted it, reports RFI.
This hesitation raises public health and equity concerns, as the vaccine notably protects against cervical cancer, a serious disease. However, the high cost of the vaccine makes it inaccessible to a large portion of the Turkish population.
Several factors explain Ankara authorities’ stance: persistent vaccine distrust, significant economic constraints, and a cultural taboo surrounding a sexually transmitted virus.